Trutino Biosciences is focused on developing innovative cytokine therapies aimed at restoring immune balance in cancer patients. Their proprietary On-Demand-Cytokine (ODC) platform allows for the systemic delivery of inactive cytokines that can be activated locally at the tumor site. This targeted approach is designed to enhance the efficacy of treatments while minimizing the severe side effects commonly associated with traditional cytokine therapies. By engineering these therapies for optimal retention and activation at the disease site, Trutino aims to safely stimulate cancer-fighting immune cells, potentially improving patient outcomes.

The company is actively engaged in the research and development of novel protease-activatable prodrugs that enhance on-target activity and reduce off-target toxicity. Their pipeline includes therapeutic candidates that leverage the ODC platform, which has shown promising results in preclinical models. Trutino's commitment to advancing cancer immunotherapy is reflected in their focus on creating therapies that can be used effectively as standalone treatments or in combination with other modalities, thereby broadening the scope of options available for cancer care.

United States

Trutino means ‘Balance’ in Latin, and this represents our strategy, namely an Rx/Dx approach for Precision Oncology Drug & Clinical Development. The company logo symbolizes well balanced wings. As it takes both wings to fly, we believe a balanced Rx/Dx drug development will ultimately deliver on the promise of Precision Oncology. Our effort focuses on ‘targeted destruction of cancer cells’ and simultaneous ‘differential activation of tumor-specific immune cells’ to maximize treatment response.

Trutino Biosciences

Company Details